GlassScriptPhysician profile
Merla Puray
NPI 1952314205
$9,919.98
in general payments reported to CMS, 2019-2025
57 companies · $1,227 in 2025
The $1,227 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,307 · 2020: $1,063 · 2021: $1,343 · 2022: $1,760 · 2023: $1,784 · 2024: $1,436 · 2025: $1,227.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,683 · Education: $465 · Long Term Medical Supply Or Device Loan: $299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,683.09 |
| Education | $464.79 |
| Long Term Medical Supply Or Device Loan | $299.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,267.67 | 2019-2025 | Kisqali |
| Astellas Pharma US INC | $1,064.37 | 2019-2025 | Vyloy, Padcev, Xospata |
| Astrazeneca Pharmaceuticals LP | $935.60 | 2019-2025 | Calquence, Tagrisso, Lynparza |
| Amgen INC. | $619.02 | 2019-2023 | Nplate, Xgeva, Vectibix |
| Merck Sharp & Dohme LLC | $527.99 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Takeda Pharmaceuticals U.S.A., INC. | $430.19 | 2019-2025 | Ninlaro, Alunbrig |
| E.R. Squibb & Sons, L.L.C. | $367.56 | 2019-2024 | |
| Abbvie INC. | $320.89 | 2019-2025 | |
| Janssen Biotech, INC. | $300.73 | 2019-2022 | |
| Aveo Pharmaceuticals, INC. | $281.92 | 2022-2025 | |
| Exelixis INC. | $269.02 | 2019-2025 | Cabometyx |
| Genzyme Corporation | $266.61 | 2019-2025 | |
| Daiichi Sankyo INC. | $222.06 | 2020-2025 | Enhertu, Datroway |
| Incyte Corporation | $217.66 | 2020-2025 | Jakafi, Niktimvo, Monjuvi |
| Eisai INC. | $213.54 | 2021-2025 |
Show all 57 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Puma Biotechnology, INC. | $200.91 | 2019-2025 | |
| Seagen INC. | $193.99 | 2020-2023 | Padcev, Tukysa, Adcetris |
| Gilead Sciences, INC. | $186.98 | 2019-2025 | Trodelvy |
| Pfizer INC. | $154.91 | 2019-2021 | |
| Lilly USA, LLC | $141.33 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Mirati Therapeutics, INC. | $138.53 | 2023-2024 | Krazati |
| Sobi, INC | $125.39 | 2024-2025 | |
| Kite Pharma, INC. | $115.99 | 2021-2022 | |
| Pharmaessentia USA Corporation | $109.75 | 2023-2025 | Besremi |
| Celgene Corporation | $105.45 | 2020-2025 | Reblozyl |
| Sanofi-Aventis U.S. LLC | $99.95 | 2019 | |
| Glaxosmithkline, LLC. | $86.91 | 2020-2025 | Ojjaara |
| Ipsen Biopharmaceuticals, INC | $77.81 | 2023 | Onivyde |
| Acrotech Biopharma INC. | $75.34 | 2021-2022 | |
| Myriad Genetic Laboratories, INC. | $56.40 | 2024-2025 | Precisetumor, Myrisk |
| Adc Therapeutics America, INC. | $55.86 | 2022-2024 | |
| Taiho Oncology, INC. | $49.78 | 2023-2024 | |
| Array Biopharma INC | $40.67 | 2021 | |
| Genentech USA, INC. | $40.34 | 2022-2023 | Phesgo |
| Stemline Therapeutics INC. | $38.87 | 2020-2025 | Orserdu |
| Rigel Pharmaceuticals, INC. | $36.51 | 2019-2020 | |
| Myovant Sciences INC. | $35.71 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $33.42 | 2022 | |
| Jazz Pharmaceuticals INC. | $31.09 | 2023 | Zepzelca |
| Caris Mpi, INC. | $29.22 | 2025 | Mi Cancer Seek |
| Karyopharm Therapeutics INC. | $27.99 | 2023 | Xpovio |
| Springworks Therapeutics, INC. | $27.09 | 2025 | Ogsiveo |
| Tersera Therapeutics LLC | $26.35 | 2025 | Quzyttir |
| Immunogen, INC. | $24.37 | 2023 | Elahere |
| Dendreon Pharmaceuticals LLC | $23.94 | 2021 | |
| Servier Pharmaceuticals LLC | $23.77 | 2023 | |
| Beigene USA, INC. | $22.93 | 2024 | Brukinsa |
| Medtronic, INC. | $22.53 | 2023 | Osteocool Rf Ablation System |
| Accord Healthcare, INC. | $20.53 | 2024 | |
| Iovance Biotherapeutics, INC. | $20.29 | 2025 | Amtagvi |
| Dilon Technologies, INC. | $19.76 | 2023 | Hemoblast Bellows |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.23 | 2024 | Gilotrif |
| Cti Biopharma Corp. | $18.45 | 2023 | Vonjo |
| Alexion Pharmaceuticals, INC. | $16.97 | 2019 | |
| G1 Therapeutics, INC. | $14.07 | 2023 | Cosela |
| Morphosys, US INC. | $14.07 | 2024 | Monjuvi |
| Helsinn Therapeutics (U.S.), INC. | $11.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Merla Puray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.